Relmada Therapeutics Stock Soars 12.26% on CEO's Insider Buying

On August 29, 2025, Relmada Therapeutics' stock surged by 12.26% in pre-market trading, marking a significant rise that has caught the attention of investors and analysts alike.

One of the key factors contributing to this surge is the recent insider trading activity reported by Sergio Traversa, the Chief Executive Officer of Relmada Therapeutics. Traversa has been actively purchasing shares of the company, acquiring a total of 266,000 shares over three days, from August 26 to August 28, 2025. This substantial investment by the CEO indicates a strong belief in the company's future prospects and has likely bolstered investor confidence.

Traversa's purchases were made at varying prices, ranging from $0.61 to $0.79 per share, reflecting a strategic approach to accumulating shares. The weighted average price of these transactions was reported to be $0.69 per share, suggesting that Traversa is confident in the company's ability to deliver value to shareholders in the long term.

This insider buying activity is a positive signal for investors, as it demonstrates that key executives are aligning their interests with those of shareholders. Such actions often precede positive developments within the company, such as new product launches, strategic partnerships, or improved financial performance. Investors are likely to view Traversa's purchases as a vote of confidence in Relmada Therapeutics' future growth potential.